A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

por Cherng, Hua-Jay J., Alig, Stefan K., Oki, Yasuhiro, Nastoupil, Loretta J., Fayad, Luis, Neelapu, Sattva S., Turturro, Francesco, Hagemeister, Fredrick, Craig, Alexander F. M., Macaulay, Charles W., Rodriguez, Maria Alma, Lee, Hun Ju, McDonnell, Timothy J., Flowers, Christopher R., Vega, Francisco, Green, Michael R., Feng, Lei, Kurtz, David M., Alizadeh, Ash A., Davis, R. Eric, Westin, Jason R.
Publicado 2022

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

por Kurtz, David M., Soo, Joanne, Keh, Lyron Co Ting, Alig, Stefan, Chabon, Jacob J., Sworder, Brian J., Schultz, Andre, Jin, Michael C., Scherer, Florian, Garofalo, Andrea, Macaulay, Charles W., Hamilton, Emily G., Chen, Binbin, Olsen, Mari, Schroers-Martin, Joseph G., Craig, Alexander F.M., Moding, Everett J., Esfahani, Mohammad S., Liu, Chih Long, Dührsen, Ulrich, Hüttmann, Andreas, Casasnovas, René-Olivier, Westin, Jason R., Roschewski, Mark, Wilson, Wyndham H., Gaidano, Gianluca, Rossi, Davide, Diehn, Maximilian, Alizadeh, Ash A.
Publicado 2021